Leveraging Molecular and Immune-Based Therapies in Leptomeningeal Metastases
Open Access
- 6 December 2022
- journal article
- review article
- Published by Springer Nature in CNS Drugs
- Vol. 37 (1) , 45-67
Abstract
Leptomeningeal metastases represent an aggressive stage of cancer with few durable treatment options. Improved understanding of cancer biology, neoplastic reliance on oncogenic driver mutations, and complex immune system interactions have resulted in an explosion in cancer-directed therapy in the last two decades to include small molecule inhibitors and immune checkpoint inhibitors. Most of these therapeutics are underexplored in patients with leptomeningeal metastases, limiting extrapolation of extracranial and even intracranial efficacy outcomes to the unique leptomeningeal space. Further confounding our interpretation of drug activity in the leptomeninges is an incomplete understanding of drug penetration through the blood–cerebrospinal fluid barrier of the choroid plexus. Nevertheless, a number of retrospective studies and promising prospective trials provide evidence of leptomeningeal activity of several small molecule and immune checkpoint inhibitors and underscore potential areas of further therapeutic development for patients harboring leptomeningeal disease.Keywords
Funding Information
- National Institutes of Health (P30 CA008748, 5R01CA245499)
This publication has 245 references indexed in Scilit:
- A Comprehensive Survey of Ras Mutations in CancerCancer Research, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Incidence of brain metastases in renal cell carcinoma treated with sorafenibAnnals of Oncology, 2010
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALKJournal of Clinical Oncology, 2009
- Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primatesCancer Chemotherapy and Pharmacology, 2009
- Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast CancerClinical Cancer Research, 2009
- A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignanciesNeuro-Oncology, 2008
- Capecitabine Therapy of Central Nervous System Metastases from Breast CancerJournal of Neuro-Oncology, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinomaCancer, 2003